Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356807 | 0.91 | HTR1A (0.40) | HTR1ADRD2HCRTR1HCRTR2ABCB1 | |
| SCHEMBL17356787 | 0.86 | HTR2C (0.40) | — | |
| SCHEMBL17356790 | 0.80 | FABP7 (0.48) | KDM1AMAOAMAOBFABP7FABP3 | |
| SCHEMBL17356791 | 0.78 | ABCB1 (0.42) | HTR1ADRD2HCRTR1HCRTR2ABCB1 | |
| SCHEMBL17356802 | 0.77 | PNMT (0.38) | EPHX2TACR1 | |
| SCHEMBL17356788 | 0.71 | HTR2C (0.50) | DRD2 | |
| SCHEMBL17356793 | 0.71 | ABCB1 (0.43) | HTR1ADRD2ABCB1 | |
| SCHEMBL16955777 | 0.70 | ABCB1 (0.53) | HTR1ADRD2HCRTR1HCRTR2ABCB1 | |
| SCHEMBL10914783 | 0.69 | MAOB (0.48) | HTR1AKDM1AMAOAMAOB | |
| SCHEMBL5680394 | 0.68 | MEN1 (0.43) | HTR1AKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313792-A1 | METHOD FOR PRODUCING POLAR GROUP-CONTAINING OLEFIN POLYMER | THE UNIVERSITY OF TOKYO (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9499644-B2 | Production method of polar group-containing olefin polymers | SHOWA DENKO K.K. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | SHOWA DENKO K.K. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | OR10J3, OPRM1, ORC3 | HTR1A 3188/4885DRD2 1606/4885KDM1A 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.